pioglitazone has been researched along with Fournier Disease in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, M | 1 |
| Mitsuhashi, K | 1 |
| Matsuda, H | 1 |
| Watanabe, J | 1 |
| Nakanishi, K | 1 |
1 other study available for pioglitazone and Fournier Disease
| Article | Year |
|---|---|
Myelodysplastic syndrome diagnosed on the occasion of Fournier's gangrene.
Topics: Aged; Anti-Bacterial Agents; Fournier Gangrene; Humans; Male; Myelodysplastic Syndromes; Pioglitazon | 2017 |